All Access

Biotech Deals

Biotech Deals Alert

Alert

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

detroit

columbus

austin

kansas-city

dallas

atlanta

washington-dc

nw-arkansas

boulder

chicago

indianapolis

nashville

richmond

houston

san-francisco

seattle

colorado-springs

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

huntsville

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

Cartography Biosciences, a developer of cancer therapies, raised a $67 million Series B, CEO Kevin Parker tells Axios Pro.

Why it matters: The financing will support the asset's Phase 1 clinical trial, expected to begin in early 2026.

How it works: Cartography's lead program, CBI-1214, is a T-cell engager to treat colorectal cancer.

The drug binds to tumor cells in the colon, recruiting T-cells to recognize and eliminate the cancer.

Follow the money: Pfizer Ventures led the Series B, and was joined by LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, Lotte Holdings CVC, a16z Bio + Health, 8VC, Wing Venture Capital, Catalio Capital Management, AME Cloud Ventures, ARTIS Ventures and Gaingels.

Cartography has now raised $124 million to date.

What's next: Parker says Cartography is open to partnerships or licensing deals with pharma partners, after announcing a $20 million strategic collaboration with Gilead Sciences in May.

"We know that we can only do so much ourselves," he says. "We've built relationships and had some nice conversations."

State of play: Cancer startups continue to attract investor interest as there's significant unmet need for the disease.

Earlier this week, Danish biotech Genmab agreed to acquire head and neck cancer company Merus in an $8 billion deal.

And Predicta Biosciences, which develops diagnostic and therapeutic tools for precision oncology, raised a $23.4 million Series A.

Catch up quick: Cartography's foundational research was completed by Parker and other scientists at Stanford University.

Cartography Biosciences raises $67M Series B for colon cancer therapy

The financing will pay for a Phase 1 clinical trial.

Illustration of a hand holding a microscope slide with a liquid sample forming a dollar sign.

Cartography Biosciences, a developer of cancer therapies, raised a $67 million Series B, CEO Kevin Parker tells Axios Pro.Why it matters: The financing will support the asset&#x27;s Phase 1 clinical trial, expected to begin in early 2026.

Cartography Biosciences raises $67M Series B for colon cancer therapy

What to read next